PharmaJet partner Immunomic Therapeutics Initiates Clinical Trial of DNA Vaccine for Skin Cancer

GOLDEN, Colo. — March 15, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that its partner Immunomic Therapeutics will be starting a phase 1 clinical study of their plasmid DNA vaccine ITI-3000 in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer.

PharmaJet Vaccine Delivery featured at Sabin Vaccine Institute Conference

GOLDEN, Colo. — March 1, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that their poster will be presented on March 1-3, 2022 at the Vaccination Acceptance Research Network (VARN) conference, sponsored by the Sabin Vaccine Institute. The poster, entitled Needle-free delivery of vaccines bridges vaccine coverage gaps in Somalia and Pakistan,.

PharmaJet partner Technovalia announces Interim results of Needle-free COVID-19 Vaccine Trial

GOLDEN, Colo. — February 15, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that their partner, Technovalia, has reported interim safety results from their needle-free SARS-CoV2 DNA vaccine phase 1 trial. Interim safety data of COVIGEN, their DNA Covid-19 vaccine candidate, is well tolerated and no safety concerns were observed.

PharmaJet CEO featured in CEOCFO Magazine

GOLDEN, Colo. — February 1, 2022 — PharmaJet®, a biotech company that has developed a more effective way of administering drugs and biologics with their innovative, needle-free injection technology, announced that Chris Cappello, President and CEO of PharmaJet was featured in CEOCFO Magazine.

The interview focused on how the Needle-free technology works, PharmaJet’s partnerships with pharmaceutical companies, and how the Colorado-based company is scaling production to meet increased customer demand.

University of Cambridge begins COVID-19 Clinical Trial Using PharmaJet’s Needle-free System

GOLDEN, Colo. — January 18, 2022 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System (NFIS) will be used in a clinical trial to deliver a booster vaccine against COVID-19 virus variants. The vaccine developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK, recently announced the start of the Phase 1 clinical trial.

PharmaJet partner Zydus Cadila announces COVID-19 vaccine expansion plan to multiple countries with Korean firm

GOLDEN, Colo. — January 4, 2022 - PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine (ZyCoV-D®) in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval (EUA) by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income countries in Latin America and Asian New Southern Policy member countries. It is exclusively delivered by the PharmaJet Tropis® Needle-free Injection System.

PharmaJet partner, Nykode Therapeutics announces phase 1/2 clinical trial with next generation DNA-based COVID-19 vaccine candidates

GOLDEN, Colo. — December 14, 2021 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that one of its pharmaceutical partners, Nykode Therapeutics (formerly Vaccibody) has begun a phase 1/2 clinical trial to specifically address emerging SARS-CoV-2 variants. The DNA-based vaccines will be delivered intramuscularly in the clinical trial exclusively using the PharmaJet Stratis® Needle-free Injection System.

PharmaJet Named Asia’s Most Innovative Vaccine Delivery System at the Vaccine World Asia Congress 2021

GOLDEN, Colo. — November 30, 2021 - PharmaJet®, the maker of innovative, needle-free injection technology, has been named “Asia’s Most Innovative Vaccine Delivery System” at the Asia-Pacific Vaccine Excellence Awards 2021 (AVEA 2021). The award was accepted by Paul LaBarre, MS, MBA, Vice President, Global Business Development, PharmaJet, Inc.